Literature DB >> 23461589

Effects of immunosuppression on circulating adeno-associated virus capsid-specific T cells in humans.

Elizabeth M Parzych1, Hua Li, Xiangfan Yin, Qin Liu, Te-Lang Wu, Gregory M Podsakoff, Katherine A High, Matthew H Levine, Hildegund C J Ertl.   

Abstract

In humans adeno-associated virus (AAV)-mediated gene transfer is followed by expansion of AAV capsid-specific T cells, evidence of cell damage, and loss of transgene product expression, implicating immunological rejection of vector-transduced cells, which may be prevented by immunosuppressive drugs. We undertook this study to assess the effect of immunosuppression (IS) used for organ transplantation on immune responses to AAV capsid antigens. Recipients of liver or kidney transplants were tested before and 4 weeks after induction of IS in comparison with matched samples from healthy human adults and an additional cohort with comorbid conditions similar to those of the transplant patients. Our data show that transplant patients and comorbid control subjects have markedly higher frequencies of circulating AAV capsid-specific T cells compared with healthy adults. On average, IS resulted in a reduction of AAV-specific CD4⁺ T cells, whereas numbers of circulating CD8⁺ effector and central memory T cells tended to increase. Independent of the type of transplant or the IS regimens, the trend of AAV capsid-specific T cell responses after drug treatment varied; in some patients responses were unaffected whereas others showed decreases or even pronounced increases, casting doubt on the usefulness of prophylactic IS for AAV vector recipients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23461589      PMCID: PMC3631016          DOI: 10.1089/hum.2012.246

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  32 in total

Review 1.  Newer immunosuppressive drugs: a review.

Authors:  J F Gummert; T Ikonen; R E Morris
Journal:  J Am Soc Nephrol       Date:  1999-06       Impact factor: 10.121

Review 2.  Manipulating immune responses with immunosuppressive agents that target NFAT.

Authors:  A Kiani; A Rao; J Aramburu
Journal:  Immunity       Date:  2000-04       Impact factor: 31.745

Review 3.  Post-transplant EBV induced lymphoproliferative disorders.

Authors:  K G Lucas; K E Pollok; D J Emanuel
Journal:  Leuk Lymphoma       Date:  1997-03

4.  CD8hi+CD57+ T lymphocytes are enriched in antigen-specific T cells capable of down-modulating cytotoxic activity.

Authors:  L Mollet; B Sadat-Sowti; J Duntze; V Leblond; F Bergeron; V Calvez; C Katlama; P Debré; B Autran
Journal:  Int Immunol       Date:  1998-03       Impact factor: 4.823

5.  Presentation of atopic disease in a large cohort of pediatric liver transplant recipients.

Authors:  P Shroff; R S Mehta; J Chinen; S J Karpen; C M Davis
Journal:  Pediatr Transplant       Date:  2012-04-11

6.  Causes of death in renal transplant recipients. A review of autopsy findings from 1966 through 1985.

Authors:  M W Scroggs; J A Wolfe; R R Bollinger; F Sanfilippo
Journal:  Arch Pathol Lab Med       Date:  1987-10       Impact factor: 5.534

Review 7.  Cytomegalovirus infections following renal transplantation.

Authors:  J Glenn
Journal:  Rev Infect Dis       Date:  1981 Nov-Dec

Review 8.  Sirolimus: its discovery, biological properties, and mechanism of action.

Authors:  S N Sehgal
Journal:  Transplant Proc       Date:  2003-05       Impact factor: 1.066

9.  DNA amplification of adeno-associated virus as a response to cellular genotoxic stress.

Authors:  A O Yalkinoglu; R Heilbronn; A Bürkle; J R Schlehofer; H zur Hausen
Journal:  Cancer Res       Date:  1988-06-01       Impact factor: 12.701

10.  Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy.

Authors:  Guang-Ping Gao; Mauricio R Alvira; Lili Wang; Roberto Calcedo; Julie Johnston; James M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

View more
  8 in total

1.  High Prevalence of Infectious Adeno-associated Virus (AAV) in Human Peripheral Blood Mononuclear Cells Indicative of T Lymphocytes as Sites of AAV Persistence.

Authors:  Daniela Hüser; Dina Khalid; Timo Lutter; Eva-Maria Hammer; Stefan Weger; Melanie Heßler; Ulrich Kalus; Yvonne Tauchmann; Karin Hensel-Wiegel; Dirk Lassner; Regine Heilbronn
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

Review 2.  Durability of transgene expression after rAAV gene therapy.

Authors:  Manish Muhuri; Daniel I Levy; Martin Schulz; Douglas McCarty; Guangping Gao
Journal:  Mol Ther       Date:  2022-03-10       Impact factor: 12.910

3.  A short hepatitis C virus NS5A peptide expression by AAV vector modulates human T cell activation and reduces vector immunogenicity.

Authors:  Winston Colon-Moran; Alan Baer; Gauri Lamture; Jack T Stapleton; Joseph W Fischer; Nirjal Bhattarai
Journal:  Gene Ther       Date:  2021-11-11       Impact factor: 4.184

4.  Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery.

Authors:  Harrison C Brown; J Fraser Wright; Shangzhen Zhou; Allison M Lytle; Jordan E Shields; H Trent Spencer; Christopher B Doering
Journal:  Mol Ther Methods Clin Dev       Date:  2014-08-06       Impact factor: 6.698

Review 5.  CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications.

Authors:  Motahareh Arjomandnejad; Acadia L Kopec; Allison M Keeler
Journal:  Biomedicines       Date:  2022-01-26

6.  Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells.

Authors:  Motahareh Arjomandnejad; Katelyn Sylvia; Meghan Blackwood; Thomas Nixon; Qiushi Tang; Manish Muhuri; Alisha M Gruntman; Guangping Gao; Terence R Flotte; Allison M Keeler
Journal:  Mol Ther Methods Clin Dev       Date:  2021-10-28       Impact factor: 5.849

7.  Gene Transfer in Adeno-Associated Virus Seropositive Rhesus Macaques Following Rapamycin Treatment and Subcutaneous Delivery of AAV6, but Not Retargeted AAV6 Vectors.

Authors:  Daniel Stone; Elizabeth J Kenkel; Michelle A Loprieno; Motoko Tanaka; Harshana S De Silva Feelixge; Arjun J Kumar; Laurence Stensland; Willimark M Obenza; Solomon Wangari; Chul Y Ahrens; Robert D Murnane; Christopher W Peterson; Hans-Peter Kiem; Meei-Li Huang; Martine Aubert; Shiu-Lok Hu; Keith R Jerome
Journal:  Hum Gene Ther       Date:  2020-11-02       Impact factor: 5.695

Review 8.  Recent progress and considerations for AAV gene therapies targeting the central nervous system.

Authors:  Erik Allen Lykken; Charles Shyng; Reginald James Edwards; Alejandra Rozenberg; Steven James Gray
Journal:  J Neurodev Disord       Date:  2018-05-18       Impact factor: 4.025

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.